Publications by authors named "Mirva H Simoneau"
Biotechnol Bioeng
February 2022
Article Synopsis
- Therapeutic proteins, such as monoclonal antibodies, traditionally require the development of stable host cell lines, which is a time-consuming process that can delay new treatments.
- During the COVID-19 pandemic, a new approach using the Leap-In Transposase® system allowed for the rapid creation of stable pools for manufacturing an anti-SARS-CoV-2 monoclonal antibody.
- This expedited process enabled the production of clinical trial material in just 4.5 months, significantly faster than the usual 12-14 month timeline, while ensuring that product quality met all necessary specifications.
